Antioxidant therapy in acute, chronic and post-endoscopic retrograde cholangiopancreatography pancreatitis: An updated systematic review and meta-analysis

Figure 5 Effect of antioxidants compared with placebo therapy on incidence. Individual and pooled relative risk (A-a), heterogeneity indicators for (A-b), and publication bias indicators for (A-c) the outcome of “all types of PEP” in the studies considering antioxidants compared to placebo therapy in 1849 patients undergoing ERCP; individual and pooled relative risk (B-a); Heterogeneity indicators (B-b); and publication bias indicators (B-c) for the outcome of “severe PEP” in the studies considering antioxidants compared to placebo therapy in 1709 patients undergoing ERCP; individual and pooled relative risk (C-a); heterogeneity indicators for (C-b); publication bias indicators (C-c) for the outcome of “moderate PEP” in the studies considering antioxidants compared to placebo therapy in 1709 patients undergoing ERCP; individual and pooled relative risk (D-a); heterogeneity indicators (D-b); publication bias indicators (D-c) for the outcome of “mild PEP” in the studies considering antioxidants compared to placebo therapy in 1709 patients undergoing ERCP. PEP: Post-endoscopic retrograde cholangiopancreatography pancreatitis; ERCP: Endoscopic retrograde cholangiopancreatography.